Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.63 |
| ▸ | BLM | P54132 | 3/20 | 0.62 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butropium SCHEMBL11561521 | 0.99 | BLM (0.64) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Butropium SCHEMBL1650524 | 0.99 | BLM (0.64) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Butropium SCHEMBL26023 | 0.99 | BLM (0.64) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Butropium SCHEMBL30185784 | 0.99 | BLM (0.64) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Bromide SCHEMBL29840597 | 0.87 | BLM (0.77) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Xenytropium SCHEMBL29361010 | 0.86 | CHRM2 (0.71) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Xenytropium SCHEMBL30428452 | 0.86 | CHRM2 (0.71) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Xenytropium SCHEMBL24707 | 0.85 | BLM (0.71) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Xenytropium SCHEMBL29371652 | 0.85 | BLM (0.71) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| SCHEMBL14652328 | 0.82 | CHRM2 (0.77) | CHRM2BLMPABPC1CYP2C19CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| WO-2025041465-A1 | METHOD FOR CONCENTRATING IONIC CHEMICAL SPECIES AND LIPID PARTICLE | 国立大学法人京都工芸繊維大学 | 2025-02-27 | — | — | WO | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CHRM2 2534/4885BLM 2326/4885PABPC1 4331/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CHRM2 315/4885BLM 416/4885PABPC1 4034/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | CHRM2 315/4885BLM 416/4885PABPC1 4034/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CHRM2 531/4885BLM 257/4885PABPC1 3943/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | CHRM2 531/4885BLM 257/4885PABPC1 3943/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CHRM2 531/4885BLM 257/4885PABPC1 3943/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | CHRM2 2161/4885BLM 2823/4885PABPC1 4654/4885 |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | CHRM2 4475/4885BLM 924/4885PABPC1 270/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CHRM2 2594/4885BLM 2433/4885PABPC1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.